RNS Number:7311S
GW Pharmaceuticals PLC
02 December 2003



For Immediate Release                                            2 December 2003


                             GW Pharmaceuticals plc
                            ("GW" or "the Company")

                            Re: Share Price Movement

GW notes recent speculation relating to the UK regulatory submission for its
Sativex product.

As GW and Bayer announced at the time of the recent extension of their marketing
agreement, the assessment by the Medicines and Healthcare products Regulatory
Authority ("MHRA") continues to proceed according to the normal regulatory
process.

There is no material new information to disclose in relation to the Company's
application to the MHRA. The normal regulatory process is ongoing and the
precise timing for completion of the assessment remains at the discretion of the
MHRA.

                                    - Ends -

Enquiries:

Weber Shandwick Square Mile
Kevin Smith                                                      020 7067 0700




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
SPMDGMGZLZKGFZG